Mobile clinic brings HIV treatment to the streets: Same-Day start could transform care for the excluded
NCT ID NCT05405751
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests a new way to help vulnerable people with HIV get diagnosed and start treatment right away using a mobile screening unit. Participants receive the once-daily pill Biktarvy on the same day they are enrolled. The goal is to see if this approach helps them stay in care and keep the virus under control over 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy)
What this could lead to
If effective, this approach could help hard-to-reach groups get HIV under control quickly and stay in care, reducing transmission and improving health outcomes.
What could go wrong
This is a small, single-group study without a comparison group, so results may not apply broadly. Side effects from the medication or challenges in keeping participants engaged could limit success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Infanta Leonor
Madrid, Spain